You are here

P&T News

September 21

Benefits of opioid addiction treatment outweigh risks of adverse effects
Those in development are at best short-term solutions
GOP takes heavy fire over pre-existing conditions
FDA and some companies dispute findings of report in NEJM

September 20

Easier-to-clean Pentax device may help limit bacterial infections

September 19

First once-daily, single-inhaler triple therapy for the disease in the U.S.
Such drugs often block the serotonin that other organs need
Proprietary delivery system deposits proven steroid deep into the nose
Patient deaths related to other combination therapies concern the agency
Detailed procedures aim to protect patients from promising treatment’s toxicities

September 18

PFS worse with bendamustine and rituximab in new study
Single-dose oral therapy treats leading gynecological infection
Injection is also approved for GEP-NETs

September 15

Panel believes GSK’s Shingrix represents an improvement over Merck’s Zostavax
In a clinical trial, the prescription-only adjunct treatment significantly increased patient adherence to abstinence
Approval based on totality of evidence from global development program showing Mvasi is highly similar to Genentech’s Avastin

September 14

Options limited for patients, whose disease often returns

Pages